Spyre Therapeutics, Inc.
SYRE
$75.43
$0.390.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 190.44M | 171.65M | 177.50M | 176.99M | 169.49M |
| Gross Profit | -190.44M | -171.65M | -177.50M | -176.99M | -169.49M |
| SG&A Expenses | 51.20M | 47.91M | 46.15M | 45.15M | 44.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 241.64M | 219.56M | 223.64M | 222.15M | 214.36M |
| Operating Income | -241.64M | -219.56M | -223.64M | -222.15M | -214.36M |
| Income Before Tax | -179.44M | -155.22M | -148.98M | -206.81M | -208.93M |
| Income Tax Expenses | 0.00 | -15.00K | -14.00K | 4.00K | 4.00K |
| Earnings from Continuing Operations | -179.44 | -155.20 | -148.97 | -206.81 | -208.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -179.44M | -155.20M | -148.97M | -206.81M | -208.93M |
| EBIT | -241.64M | -219.56M | -223.64M | -222.15M | -214.36M |
| EBITDA | -- | -- | -61.07M | -116.27M | -160.23M |
| EPS Basic | -2.07 | -1.93 | -2.03 | -2.94 | -3.01 |
| Normalized Basic EPS | -1.91 | -1.58 | -1.70 | -2.43 | -2.48 |
| EPS Diluted | -2.07 | -1.93 | -2.03 | -2.94 | -3.01 |
| Normalized Diluted EPS | -1.91 | -1.58 | -1.70 | -2.43 | -2.48 |
| Average Basic Shares Outstanding | 274.39M | 256.10M | 236.27M | 226.75M | 211.80M |
| Average Diluted Shares Outstanding | 274.39M | 256.10M | 236.27M | 226.75M | 211.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |